Table 4 Comparison of PFS in patients receiving T-DM1 in lines of treatment 1–2 as compared to 3–10
Characteristics | Lines 1–2 n = 24 | Lines 3–10 n = 27 | Total n = 51 |
|---|---|---|---|
Progression | |||
No | 7 (29.2%) | 3 (11.1%) | 10 (19.6%) |
Yes | 17 (70.8%) | 24 (88.9%) | 41 (80.4%) |
PFS according to Kaplan-Meier (months) | |||
Median | 9.41 | 6.41 | 9.01 |
CI95 | (3.59–18.88) | (2.80–11.74) | (4.87–11.41) |
Minimum | 1.1 | 1.7 | 1.1 |
Maximum | 31.2 | 55.5 | 55.5 |
Intergroup comparison (Logrank test) | |||
p-value | 0.346 | ||
PFS rate | |||
1 year | 35.7% | 29.6% | 34.2% |
2 years | 35.7% | 12.7% | 19.2% |
3 years | 11.5% | 12.7% | 14.4% |
4 years | NA | 6.4% | 7.2% |